478837-18-2

Usage

Uses

Used in Pharmaceutical Industry:
Tert-Butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate is used as a potential pharmaceutical agent for its possible biological activity. Its complex structure and functional groups may contribute to its interaction with biological targets, offering opportunities for drug development and therapeutic applications.
Used in Chemical Industry:
In the chemical industry, tert-Butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate may serve as a building block or intermediate in the synthesis of more complex molecules or materials. Its unique structural features could be leveraged to create novel chemical entities with specific properties for various applications.
Further research and testing are required to fully explore the properties and potential uses of this chemical compound, ensuring its safety and efficacy in practical applications.

Upstream product

• 185099-67-6 Boc-tropinone 
• 7432-11-3 8-azabicyclo[3.2.1]octan-3-ol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 25602-68-0 3-oxo-8-azabicyclo[3.2.1]octane hydrochloride 

Downstream Products

• 1211875-54-5 3-phenoxy-8-azabicyclo[3.2.1]octane 
• 130753-13-8 benzyl 3-oxo-8-azabicyclo[3,2,1]octane-8-carboxylate 
• 5632-84-8 nortropinone 
• 185099-67-6 Boc-tropinone 
• 856900-26-0 3-cyano-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Protein degradation targeting chimera for degrading androgen receptor

The invention relates to a novel difunctional molecule compound based on VHL ligand induction and application of the difunctional molecule compound in synthesis of the compounds and pharmaceutical compositions thereof. The compound is shown as a formula I. The compound can selectively induce AR protein degradation and can be used for treating cancers such as prostatic cancer and breast cancer.

QUINAZOLINE DERIVATIVE AND USE THEREOF

The present invention relates to a series of quinazoline compounds, especially compounds as represented by formula (I), isomers thereof or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and use thereof as Pan-HER tyrosine kinase inhibitors.

Compound and application thereof

The invention provides a novel compound. The novel compound has certain inhibitory activity for indoleamine 2,3-dioxygenase (IDO) which is oxido-reductase, and accordingly the novel compound can be used for treating diseases related to the indoleamine 2,3-dioxygenase and can be applied to cancer and immunity related diseases.

Sulfonamide compound, preparation method and medical application thereof

The invention relates to a sulfonamide compound, a preparation method and medical application thereof. Specially, the invention relates to a compound shown as a general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound, and application thereof as an agonist of farnesoid X receptor (FXR). The compound and the pharmaceutical composition containing the compound can be used for treating and/or preventing diseases associated with FXR activity, such as cholestatic disorders, diabetes and complications thereof, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatosis heptitis (NASH), obesity or metabolic syndromes (dyslipidemia, diabetes and combined disorders with abnormally high body mass indexes) and cardiovascular diseases. The definitions of each substituent in the general formula (I) are the same as those in the specification.

BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds. 9936396.1

BENZOXAZEPINES AS INHIBITORS OF MTOR AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural formula wherein the combination of R1 and R2 are

PYRIMIDINE DERIVATIVES AS GPCR MODTTLATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES

The present invention relates to Pyriraidine Derivatives of formula (I), compositions comprising a Pyrimidine Derivative, and methods of using the Pyrimidine Derivatives for treating or preventing obesity, diabetes, a diabetic complication, a metabolic di

BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention al

IL-8 Receptor Antagonists

This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Tetrahydroquinoline analogues as muscarinic agonists

The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.